Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tezspire | tezepelumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Symdeko | tezacaftor/ivacaftor | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
Egrifta | Tesamorelin | Lipodystrophy, HIV-infected patients | Do not reimburse | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis, glucocorticoid induced | Do not list | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis (in women), Severe | Do not list | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Do not list | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
Aubagio | Teriflunomide | Multiple sclerosis, relapsing-remitting | Do not list at the submitted price | Complete |